Next issueIssue 23 · Tue 17 Nov 

Trials

2023-510488-36-01

Trial ID
T-ctis-2023-510488-36-01
Registry
EU Clinical Trials Information System
CTIS number
2023-510488-36-01
Sponsor, as registered
Universitair Medisch Centrum Groningen
Phase
Therapeutic exploratory (Phase II)
Indication
Chronic obstructive pulmonary disease (COPD), amyotrophic lateral sclerosis (ALS), multiple sclerosis (MS), and atypical Parkinson disorder (APD), particularly multiple system atrophy (MSA), progressive supranuclear palsy (PSP), and corticobasal syndrome (CBS).
Status
Authorised
Start date
2025-06-01
Primary completion
CTIS does not publish one.
Member states concerned
Czechia, Denmark, Netherlands, Portugal
Sites
4

Member states whose regulator has a decision on this trial.

euclinicaltrials.euctis registryverified 2026-11-07

Notes on the record

Supersedes the row verified 2026-09-28 (kept), per DATA LAYER rule 4. Read from the CTIS public API retrieve endpoint 2026-11-07 (https://euclinicaltrials.eu/ctis-public-api/retrieve/2023-510488-36-01; response sha256 c570f57f9b4c). primary_completion_date is EMPTY because CTIS does not publish one. Per-state authorisation is NOT recorded and status codes are recorded verbatim, not decoded: the registry publishes no key. Portugal lastDecisionDate 2026-11-05T13:09:45 (was 2026-06-17); Czechia 2026-06-17, Netherlands 2026-09-22, Denmark 2026-04-28; member states CZ, DK, NL, PT unchanged. The API does not expose what the decision was. Title on the record: PsyPal; Psilocybin Therapy for Psychological Distress in Palliative Patients (the indication column carries the earlier row's text, kept).

Cited in

Issues quoting 2023-510488-36-01 in their own text.

Record history